Medical Psilocybin and Psilocin Access

Summary#

This bill changes federal drug laws so psilocin and psilocybin can be used for medical treatment under existing “narcotic” rules. It also says Health Canada must automatically grant “priority review” when companies ask to fast-track review of new drugs that are psilocin, psilocybin, or very close in structure. The stated goal is to improve access to medical treatment with hallucinogens without skipping any safety or approval steps.

Key changes:

• Adds psilocin and psilocybin to the definition of “narcotic” for the Narcotic Control Regulations (the federal rules that govern how narcotics are prescribed, stored, and dispensed).
• Removes psilocin and psilocybin from the definition of “restricted drugs” under Part J of the Food and Drug Regulations (a category with tighter limits often used for research-only access).
• Makes any request for “priority review” of a new drug that is psilocin, psilocybin, or has a substantially similar chemical structure automatically approved on the day Health Canada receives it.
• Clarifies that for midwives, nurse practitioners, and podiatrists, “narcotic” covers only the controlled substances they are allowed to handle under existing New Classes of Practitioners Regulations.
• States that the bill is meant to improve medical access, not to bypass the normal new drug approval process.

What it means for you#

• Patients

  • If a psilocin or psilocybin product is approved as a new drug, you could get it by prescription, subject to the strict rules that apply to narcotics (secure handling, records, no over‑the‑counter sales).
  • Non‑medical possession, sale, or use would still be illegal. This bill does not legalize non‑medical use.
  • What is unclear: The bill does not set which conditions qualify, who is eligible, dosing, or whether public plans would cover the cost.

• Doctors and other authorized practitioners

  • Physicians, and where permitted, midwives, nurse practitioners, and podiatrists could prescribe and handle psilocin and psilocybin as “narcotics,” following the Narcotic Control Regulations and any limits in the New Classes of Practitioners Regulations.
  • You would need to meet narcotic‑level requirements for prescribing, secure storage, record‑keeping, and dispensing orders.

• Pharmacists, pharmacies, and hospitals

  • You could receive, store, compound, and dispense psilocin and psilocybin under narcotic rules (e.g., secure storage, inventory controls, documentation).
  • Existing narcotic handling systems would likely apply to these substances.

• Drug developers and manufacturers

  • New drug submissions for psilocin, psilocybin, or substances with a “substantially similar” chemical structure would get automatic priority review. This can shorten review timelines but does not guarantee approval.
  • You must still provide full safety, quality, and effectiveness evidence and meet all Food and Drugs Act and Food and Drug Regulations requirements.

• Researchers and licensed dealers

  • Psilocin and psilocybin would no longer be “restricted drugs” under Part J. Activities would instead fall under the narcotic rules. Licences and permits under those rules would still be required where applicable.

• Regulators

  • Health Canada would need to treat qualifying submissions as priority reviews and oversee narcotic‑level compliance for medical use of these substances.

• Timing

  • The provided text does not state a start date. New rules would take effect when the law starts, which is not specified here.

Expenses#

No publicly available information.

Possible cost and burden areas:

• Health Canada may face higher workload to conduct more priority reviews and to oversee compliance and licensing for medical use of these substances.
• Pharmacies, clinics, and hospitals that choose to handle these drugs may incur costs for secure storage, record‑keeping, and training, as required for narcotics.
• Drug makers would still face normal new drug submission costs; automatic priority review could reduce time to decision but does not change evidence or approval standards.
• The bill does not address public drug plan coverage or provincial health system costs.

Proponents' View#

• The bill appears intended to create a clear, legal medical pathway to psilocin and psilocybin under strict narcotic controls.
• Moving these substances out of the “restricted drug” category could enable clinical use rather than limiting access mainly to research settings.
• Automatic priority review could speed access to promising therapies while keeping the full safety and efficacy review in place.
• Using existing narcotic rules may improve oversight, with known requirements for prescribing, storage, tracking, and prevention of diversion.
• Clarifying which practitioners may handle these drugs under existing practitioner regulations may strengthen accountability and patient safety.

Opponents' View#

• One concern is that “automatic” priority status could strain Health Canada resources or shift attention away from other urgent drugs, even though it does not change approval standards.
• The phrase “substantially similar chemical structure” is not defined in the bill and could be seen as too broad, extending automatic priority to many compounds without clear evidence of need or benefit.
• Reclassifying these substances from “restricted drugs” to “narcotics” could raise risks of diversion or misuse if controls, training, and guidance are not robust and consistent.
• The bill does not set clinical guidelines, patient eligibility, dosing standards, or product quality specifics, leaving key details to future policies and approvals.
• It is unclear how provincial rules on prescribing scope, clinical practice, and drug coverage would interact with these federal changes.